FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1568436845> ?p ?o ?g. }

• W1568436845 endingPage "65" @default.
• W1568436845 startingPage "56" @default.
• W1568436845 abstract "Epidermal growth factor receptor tyrosine kinase inhibitors are useful in treatment of non-small cell lung cancer, and show promise in combination therapy settings. Two novel chiral pyrrolopyrimidines have been baselined towards Erlotinib, Lapatinib and Dasatinib using in vitro cellular studies and ADME profiling. One of these, (S)-2-((6-(4-(hydroxymethyl)-2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol, was more active than Erlotinib in lung and breast cancer cell models. The compound also had promising activity towards ovarian cancer cell lines, while low activity was seen towards cells of haematological origin. ADME profiling revealed good solubility, higher metabolic stability than Erlotinib and no inhibitory effect towards the hERG voltage-gated ion channel. Investigation of inhibitory potency towards 6 CYP isoforms generally revealed low inhibitory potency, but in the case of CYP3A4, a substrate dependent inhibition was noted using testosterone as substrate (IC50: 12.5μM). No cellular or gene toxicity was noted for the compounds or products of phase I metabolism. However, permeability studies using Caco-2 cells revealed a high efflux ratio. Further experiments using ABC transporter inhibitors revealed that the pyrrolopyrimidines are actively transported by the breast cancer resistant protein and P-glycoprotein transporters, which might prevent their further development into drugs." @default.
• W1568436845 created "2016-06-24" @default.
• W1568436845 creator A5007098021 @default.
• W1568436845 creator A5066430526 @default.
• W1568436845 creator A5069201284 @default.
• W1568436845 creator A5083097109 @default.
• W1568436845 date "2015-12-01" @default.
• W1568436845 modified "2023-09-27" @default.
• W1568436845 title "In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib" @default.
• W1568436845 cites W1495762156 @default.
• W1568436845 cites W1500036797 @default.
• W1568436845 cites W1963482243 @default.
• W1568436845 cites W1975764972 @default.
• W1568436845 cites W1979389466 @default.
• W1568436845 cites W1982044762 @default.
• W1568436845 cites W1986026085 @default.
• W1568436845 cites W1987367854 @default.
• W1568436845 cites W1988142400 @default.
• W1568436845 cites W1988369030 @default.
• W1568436845 cites W1988698939 @default.
• W1568436845 cites W1997870940 @default.
• W1568436845 cites W1999886291 @default.
• W1568436845 cites W2002714857 @default.
• W1568436845 cites W2004958423 @default.
• W1568436845 cites W2005202092 @default.
• W1568436845 cites W2011858503 @default.
• W1568436845 cites W2015878053 @default.
• W1568436845 cites W2022971046 @default.
• W1568436845 cites W2024741431 @default.
• W1568436845 cites W2035590944 @default.
• W1568436845 cites W2035721831 @default.
• W1568436845 cites W2038670745 @default.
• W1568436845 cites W2039787365 @default.
• W1568436845 cites W2049058992 @default.
• W1568436845 cites W2050240006 @default.
• W1568436845 cites W2050872970 @default.
• W1568436845 cites W2052853384 @default.
• W1568436845 cites W2066122607 @default.
• W1568436845 cites W2066567180 @default.
• W1568436845 cites W2067282464 @default.
• W1568436845 cites W2067884089 @default.
• W1568436845 cites W2072218566 @default.
• W1568436845 cites W2074166497 @default.
• W1568436845 cites W2074350030 @default.
• W1568436845 cites W2076136110 @default.
• W1568436845 cites W2082183475 @default.
• W1568436845 cites W2082871870 @default.
• W1568436845 cites W2083527129 @default.
• W1568436845 cites W2086896374 @default.
• W1568436845 cites W2090029719 @default.
• W1568436845 cites W2090148260 @default.
• W1568436845 cites W2094409040 @default.
• W1568436845 cites W2099354673 @default.
• W1568436845 cites W2101439546 @default.
• W1568436845 cites W2113341349 @default.
• W1568436845 cites W2117909144 @default.
• W1568436845 cites W2121389240 @default.
• W1568436845 cites W2122871705 @default.
• W1568436845 cites W2124967121 @default.
• W1568436845 cites W2127960972 @default.
• W1568436845 cites W2139131914 @default.
• W1568436845 cites W2139519829 @default.
• W1568436845 cites W2141527855 @default.
• W1568436845 cites W2150213614 @default.
• W1568436845 cites W2150525034 @default.
• W1568436845 cites W2155014490 @default.
• W1568436845 cites W2157036356 @default.
• W1568436845 cites W2159459001 @default.
• W1568436845 cites W2168964329 @default.
• W1568436845 cites W2335707062 @default.
• W1568436845 cites W2418690536 @default.
• W1568436845 cites W622062215 @default.
• W1568436845 cites W76063910 @default.
• W1568436845 doi "https://doi.org/10.1016/j.ejps.2015.08.003" @default.
• W1568436845 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26296860" @default.
• W1568436845 hasPublicationYear "2015" @default.
• W1568436845 type Work @default.
• W1568436845 sameAs 1568436845 @default.
• W1568436845 citedByCount "10" @default.
• W1568436845 countsByYear W15684368452016 @default.
• W1568436845 countsByYear W15684368452017 @default.
• W1568436845 countsByYear W15684368452018 @default.
• W1568436845 countsByYear W15684368452019 @default.
• W1568436845 countsByYear W15684368452021 @default.
• W1568436845 countsByYear W15684368452022 @default.
• W1568436845 crossrefType "journal-article" @default.
• W1568436845 hasAuthorship W1568436845A5007098021 @default.
• W1568436845 hasAuthorship W1568436845A5066430526 @default.
• W1568436845 hasAuthorship W1568436845A5069201284 @default.
• W1568436845 hasAuthorship W1568436845A5083097109 @default.
• W1568436845 hasConcept C104317684 @default.
• W1568436845 hasConcept C109650736 @default.
• W1568436845 hasConcept C112705442 @default.
• W1568436845 hasConcept C121608353 @default.
• W1568436845 hasConcept C126322002 @default.
• W1568436845 hasConcept C149011108 @default.
• W1568436845 hasConcept C170493617 @default.
• W1568436845 hasConcept C185592680 @default.

• next